Drug Administration via Endotracheal Tube: Still Relevant?

Endobronchial drug administration via the endotracheal tube is one of those techniques that many emergency medicine practitioners still remember from their training – but that has increasingly faded into the background in modern resuscitation medicine. For a long time, it was considered an acceptable alternative when intravenous access could not be established. However, the AHA guidelines have fundamentally revised this recommendation. This article examines the pharmacokinetic principles, the available evidence, and the practical implications for clinical practice – and answers the question of whether endotracheal drug administration still has a place in the emergency medicine repertoire.

Historical Context: How Endotracheal Administration Became Standard

The idea of administering drugs via the endotracheal tube is based on the observation that the pulmonary alveoli offer an enormous absorptive surface area – approximately 70–100 m² in adults. As early as the 1960s and 1970s, animal studies demonstrated that epinephrine and lidocaine produced measurable plasma levels after endobronchial administration. In an era when intraosseous access (i.o.) was not yet an established standard procedure and peripheral venipuncture frequently failed under resuscitation conditions, the endotracheal route appeared to be a pragmatic solution.

The recommendation was incorporated into international guidelines and taught in courses for decades. The acronym NAVEL (Naloxone, Atropine/Adrenaline, Vasopressin, Epinephrine, Lidocaine) – also known in English-speaking countries as LEAN or LANE – helped generations of emergency medicine practitioners remember the substances that could be administered endobronchially.

Pharmacokinetics of Endobronchial Administration

Absorption Mechanism

Pulmonary absorption occurs across the alveolocapillary membrane. Drugs applied to the bronchial mucosa and alveolar surface must first pass through the surfactant film, the alveolar epithelium, and the capillary endothelium before reaching the pulmonary circulation. This process depends on several factors:

• Lipophilicity of the drug: Lipophilic substances (e.g., lidocaine, atropine) are absorbed significantly better than hydrophilic ones.
• Pulmonary perfusion: Under resuscitation conditions, pulmonary perfusion is massively reduced – even with optimal chest compressions, cardiac output only reaches 25–30% of normal values. This substantially limits absorption.
• Dilution effect: Drugs that remain in the bronchial system are diluted by secretions, blood, and edema fluid, reducing the effective concentration at the absorptive surface.
• Ventilation status: Adequate distribution of the drug to the lung periphery requires sufficient ventilation – which is not always achievable under CPR conditions.

Bioavailability and Dose Adjustment

Central to understanding the problem is the significantly reduced and, above all, unpredictable bioavailability. Studies show that plasma levels after endotracheal administration compared to intravenous administration are:

• Lower (often only 10–40% of i.v. levels)
• Delayed in onset (peak at 3–5 minutes instead of seconds)
• More variable (large interindividual differences)

For this reason, it was traditionally recommended to increase the endotracheal dose to 2 to 2.5 times the standard intravenous dose. For epinephrine, this meant:

Drug	i.v. Dose	Endotracheal Dose	Dilution Volume
Epinephrine	1 mg	2–2.5 mg	5–10 mL normal saline
Atropine	1 mg	2–3 mg	5–10 mL normal saline
Lidocaine	1–1.5 mg/kg	2–3 mg/kg	5–10 mL normal saline
Naloxone	0.4–2 mg	0.8–5 mg	5–10 mL normal saline

The drug should be diluted in 5–10 mL of normal saline and administered via a catheter advanced deep into the tube, followed by several forceful ventilation breaths to distribute it into the lung periphery.

The Problem: Why Theory Fails in Practice

Insufficient Evidence for Clinical Efficacy

The data on endobronchial drug administration under resuscitation conditions is sobering. There are no randomized controlled trials (RCTs) demonstrating a survival benefit from endotracheally administered epinephrine compared to no epinephrine or to i.v./i.o. epinephrine during CPR.

What the available evidence shows:

• Animal experimental data do confirm absorption, but plasma levels measured under laboratory conditions cannot be directly extrapolated to the resuscitation setting in humans.
• Retrospective clinical studies show that patients who received epinephrine endotracheally tended to have worse outcomes than those with i.v. access. However, this association is confounded by selection bias – patients without i.v. access may have had a poorer prognosis per se.
• Pharmacological studies in resuscitation patients document that plasma levels achieved after endotracheal administration frequently fall below the therapeutically effective threshold.

The Depot Problem

A particularly relevant aspect that is often underestimated in clinical discussion: epinephrine deposited on the bronchial mucosa can be absorbed abruptly after return of spontaneous circulation (ROSC). The resulting "wash-out" phase leads to uncontrollably high plasma levels that can:

• Trigger severe tachycardia and hypertension
• Worsen the myocardial oxygen balance
• Promote reperfusion arrhythmias
• Destabilize the just-restored circulation

This phenomenon is particularly pronounced with the 2 to 2.5-fold dosing and represents a significant safety risk in the post-ROSC phase.

Reduced Pulmonary Perfusion as the Core Problem

The fundamental problem can be reduced to a simple physiological relationship: endobronchial drug administration requires adequate pulmonary perfusion for absorption. However, this perfusion is precisely what is massively impaired under resuscitation conditions. This creates a pharmacological paradox:

• The drug (e.g., epinephrine) is supposed to restore circulation.
• For its absorption, however, it requires a functioning circulation.
• Under CPR conditions, pulmonary perfusion is so low that absorption becomes unreliable.

Intraosseous Access as the Superior Alternative

Why I.O. Instead of Endotracheal?

Intraosseous access has completely replaced endobronchial drug administration as the preferred alternative access route. The reasons are compelling:

• Rapid placement: An i.o. access can typically be established within 30–60 seconds – often faster than peripheral venous access under resuscitation conditions.
• Reliable bioavailability: Drugs administered intraosseously reach the central venous circulation via the bone marrow sinusoids. Bioavailability is comparable to intravenous administration.
• No dose adjustment required: The same dosages apply as for i.v. administration.
• Predictable pharmacokinetics: Onset times are only slightly slower than with i.v. administration and are not clinically significantly delayed under CPR conditions.
• Broad drug spectrum: Virtually all emergency drugs and infusion solutions can be administered via the i.o. route – not just the few substances covered by the NAVEL acronym.
• High success rate: The first-attempt success rate is above 85–90% for trained providers.

Insertion Sites and Systems

Several insertion sites are available for emergencies:

• Proximal tibia (standard site): 1–2 cm medial and distal to the tibial tuberosity
• Distal tibia: Above the medial malleolus
• Proximal humerus: At the greater tubercle (particularly good flow rates, but technically more demanding)
• Distal femur (primarily pediatric): 1–2 cm proximal to the lateral femoral condyle

Common systems include semi-automatic drill devices (e.g., EZ-IO®) and manual systems. The choice of system should depend on availability and team training.

What Do Current Guidelines Say?

The AHA guidelines formulate a clear hierarchy of access routes during CPR:

1. Intravenous access (i.v.) – remains the gold standard
2. Intraosseous access (i.o.) – equivalent alternative when i.v. is not rapidly achievable
3. Endotracheal administration – is no longer recommended

The AHA guidelines use explicit language: i.o. access is recommended as the preferred alternative access route when peripheral venipuncture fails or takes too long. Endotracheal drug administration is no longer listed as a routine alternative.

The European Resuscitation Council (ERC) holds a comparable position and classifies endobronchial administration as obsolete as long as i.o. systems are available.

Is There Still an Indication?

The honest answer is: theoretically yes, practically hardly ever. A hypothetical scenario in which endotracheal administration might still be considered would be:

• Intubated patient in cardiac arrest
• No i.v. access obtainable
• No i.o. equipment available
• No timely resupply possible

In such a scenario – which is extremely rare in modern emergency medicine – endotracheal administration of epinephrine would be justifiable as an absolute last resort. Administration should then proceed as follows:

1. Dilute 2–2.5 mg epinephrine in 10 mL normal saline
2. Advance a long, flexible catheter through the tube to just above the carina
3. Rapidly instill the drug
4. Remove the catheter
5. Deliver 3–5 forceful ventilation breaths for distribution
6. Continue chest compressions

It should be emphasized: this situation should be actively avoided through proactive equipment preparation and training.

Special Considerations in Pediatrics

In pediatric emergency medicine, endotracheal drug administration was historically particularly widespread, as peripheral venipuncture in infants and small children under resuscitation conditions is notoriously difficult. It is precisely here that i.o. access has brought the greatest improvement:

• The proximal tibia can be safely accessed even in neonates and infants.
• The success rate is high, the complication rate low.
• The PALS guidelines recommend i.o. access as the primary alternative to i.v. access – endotracheal administration is no longer recommended here either.

Summary Assessment

A critical analysis of the evidence yields a clear picture:

Criterion	Endotracheal	Intraosseous
Bioavailability	Low, variable	High, predictable
Dose adjustment required	Yes (2–2.5-fold)	No
Onset time	Delayed, unpredictable	Comparable to i.v.
Drug spectrum	NAVEL only	Nearly all
Post-ROSC risk	Depot effect possible	No depot effect
Quality of evidence	Weak	Moderate to good
Guideline recommendation	No longer recommended	Recommended

Endotracheal drug administration is a historically understandable but, according to current evidence, obsolete method. It offers no advantage over i.o. access while presenting considerable pharmacological disadvantages. The unreliable absorption under the pathophysiological conditions of cardiac arrest, the need for dose escalation with consequent post-ROSC risk, and the limited drug spectrum make it the inferior method.

For clinical practice, this means: every emergency team should have i.o. equipment available and regularly train in its use. Knowledge of endotracheal administration still has a place in emergency medicine education – as historical understanding and for the absolute exceptional situation – but no longer as a standard procedure.

Practical Training

The hierarchy of access routes during CPR, safe placement of an i.o. access, and correct drug administration within the ACLS algorithm are core competencies that should be trained regularly. In the ACLS Refresher Course by Simulation Tirol, you practice these skills hands-on in realistic scenarios – including the decision of when to choose which access route and how to ensure the correct drug dosing under time pressure. Precisely because guideline recommendations continue to evolve, regular, structured refresher training is essential to act according to current standards in a real emergency.

---